Eclipse XL1 System
Short Bowel Syndrome (SBS)
Feasibility StudyActive
Key Facts
About Eclipse Regenesis
Eclipse Regenesis is developing the first device-based therapy aimed at regenerating intestinal tissue in patients with Short Bowel Syndrome (SBS), a severe and costly condition. Its Eclipse XL1 System is an implantable coil that applies gentle pressure to the intestine to stimulate natural growth (distraction enterogenesis), addressing the root cause of malabsorption. The company is currently conducting a feasibility study in partnership with leading pediatric hospitals and operates as a private, pre-revenue entity focused on bringing this regenerative approach to market.
View full company profile